The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a huge mover today! About 1.59M shares traded hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 34.32% since April 4, 2016 and is downtrending. It has underperformed by 35.42% the S&P500.
The move comes after 7 months positive chart setup for the $311.64M company. It was reported on Nov, 4 by Barchart.com. We have $7.92 PT which if reached, will make NASDAQ:CLDX worth $492.39M more.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage
Out of 11 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 6 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 55% are positive. Celldex Therapeutics has been the topic of 15 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was downgraded by Oppenheimer on Monday, March 7 to “Perform”. The firm has “Buy” rating by Brean Capital given on Tuesday, August 11. Jefferies downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Tuesday, March 8 to “Hold” rating. The firm has “Market Perform” rating given on Monday, March 7 by Leerink Swann. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Outperform” rating given on Tuesday, March 8 by Cowen & Co. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Hold” rating by Jefferies on Tuesday, August 9. Cantor Fitzgerald maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Friday, February 26 with “Buy” rating. The firm has “Buy” rating by TH Capital given on Tuesday, August 11. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Neutral” rating given on Monday, March 7 by Guggenheim. The firm has “Outperform” rating given on Tuesday, August 11 by Oppenheimer.
According to Zacks Investment Research, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.”
More news for Celldex Therapeutics, Inc. (NASDAQ:CLDX) were recently published by: Fool.com, which released: “Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.” on October 25, 2016. Fool.com‘s article titled: “Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc.” and published on October 18, 2016 is yet another important article.
CLDX Company Profile
Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Firm drug candidates are derived from a set of complementary technologies, which have the ability to utilize the human immune system and enable the creation of therapeutic agents. The Firm is using the technologies to develop targeted immunotherapeutics consist of protein molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). The Company’s Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. The Company’s Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.